9-valent human papillomavirus recombinant vaccine / Shanghai Bovax Biotech - LARVOL DELTA

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males (clinicaltrials.gov) - P3 | N=9000 | Active, not recruiting | Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Anal Carcinoma • Genito-urinary Cancer • Oncology • Penile Cancer • Solid Tumor

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males (clinicaltrials.gov) - P3 | N=9000 | Recruiting | Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Anal Carcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Penile Cancer • Solid Tumor

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males (clinicaltrials.gov) - P3 | N=9000 | Not yet recruiting | Sponsor: Shanghai Bovax Biotechnology Co., Ltd.

New P3 trial • Anal Carcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Penile Cancer • Solid Tumor

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old (clinicaltrials.gov) - P1 | N=90 | Completed | Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Nov 2023 | Trial primary completion date: Sep 2024 ➔ Nov 2023

Trial completion • Trial completion date • Trial primary completion date • Anal Carcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Penile Cancer • Solid Tumor

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Anal Carcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Penile Cancer • Solid Tumor

Evaluate the Safety and Immunogenicity of a 9vHPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Shanghai Bovax Biotechnology Co., Ltd.

New P1 trial • Anal Carcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Penile Cancer • Solid Tumor

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (clinicaltrials.gov) - P3 | N=1680 | Completed | Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Dec 2021 ➔ Sep 2021 | Trial primary completion date: Dec 2021 ➔ Sep 2021

Trial completion • Trial completion date • Trial primary completion date • Cervical Cancer • Gynecologic Cancers • Oncology • Solid Tumor • Vaginal Cancer • Vulvar Cancer

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years (clinicaltrials.gov) - P3 | N=1200 | Recruiting | Sponsor: Shanghai Bovax Biotechnology Co., Ltd. | Trial primary completion date: Dec 2021 ➔ May 2026

Trial primary completion date • Cervical Cancer • Gynecologic Cancers • Infectious Disease • Oncology • Solid Tumor • Vaginal Cancer • Vulvar Cancer

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years (clinicaltrials.gov) - P3; N=1200; Recruiting; Sponsor: Shanghai Bovax Biotechnology Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Cervical Cancer • Gynecologic Cancers • Infectious Disease • Oncology • Solid Tumor • Vaginal Cancer • Vulvar Cancer

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years (clinicaltrials.gov) - P3; N=1200; Not yet recruiting; Sponsor: Shanghai Bovax Biotechnology Co., Ltd.

Clinical • New P3 trial • Cervical Cancer • Gynecologic Cancers • Infectious Disease • Oncology • Solid Tumor • Vaginal Cancer • Vulvar Cancer

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (clinicaltrials.gov) - P3; N=1680; Recruiting; Sponsor: Shanghai Bovax Biotechnology Co., Ltd.

Clinical • New P3 trial • Cervical Cancer • Gynecologic Cancers • Oncology • Solid Tumor • Vaginal Cancer

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (clinicaltrials.gov) - P3; N=9600; Recruiting; Sponsor: Shanghai Bovax Biotechnology Co., Ltd.

Clinical • New P3 trial • Cervical Cancer • Gynecologic Cancers • Oncology • Solid Tumor • Vaginal Cancer